Home › Compare › PBLA vs QYLD

PBLA vs QYLD: Dividend Comparison 2026

PBLA yields 1000000.00% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBLA wins by $4.7683925249533696e+36M in total portfolio value
10 years
PBLA
PBLA
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full PBLA calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — PBLA vs QYLD

📍 PBLA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBLAQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBLA + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PBLA pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBLA
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, PBLA beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBLA + QYLD for your $10,000?

PBLA: 50%QYLD: 50%
100% QYLD50/50100% PBLA
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PBLA right now

PBLA
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
-60.8
Piotroski
4/9
QYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBLA buys
0
QYLD buys
1
PoliticianChamberTickerTypeAmountDate
Tim Moore🏢 House$QYLD▼ Sell$15,001 - $50,0002025-05-02
Tim Moore🏢 House$QYLD▲ Buy$15,001 - $50,0002025-04-07
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002022-11-14
Dwight Evans🏢 House$QYLD▼ Sell$1,001 - $15,0002020-10-29
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBLAQYLD
Forward yield1000000.00% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.7683925249533696e+36M$25.4K ✓
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓$5,659.31
Total dividends collected$4.7683311610149396e+36M$27.1K ✓
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: PBLA vs QYLD ($10,000, DRIP)

YearPBLA PortfolioPBLA Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$100,010,700$100,000,000.00$10,352$1,192.36+$100.00M → PBLA
2$934,786,450,701$934,679,439,252.34$10,830$1,347.57+$934786.44M → PBLA
3$8,165,787,108,578,292$8,164,786,887,076,042.00$11,460$1,539.07+$8165787108.57M → PBLA
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$12,275$1,777.84+$66665884190957.64M → PBLA
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$13,323$2,078.95+$508662171058048128.00M → PBLA
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$14,667$2,463.34+$3.62723524842849e+21M → PBLA
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$16,396$2,960.57+$2.417368115915061e+25M → PBLA
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$18,631$3,612.97+$1.5056740286145463e+29M → PBLA
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$21,548$4,482.15+$8.764771002818475e+32M → PBLA
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$25,398$5,659.31+$4.7683925249533696e+36M → PBLA

PBLA vs QYLD: Complete Analysis 2026

PBLA — Stock

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Full PBLA Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this PBLA vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBLA vs SCHDPBLA vs JEPIPBLA vs OPBLA vs KOPBLA vs MAINPBLA vs XYLDPBLA vs JEPQPBLA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.